Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Last trade$110.59
Day change+$5.55 (+5.28%)
Day range$102.90 – $111.43
Volume1,028,044
Market cap$6.96B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.96B
Price / earnings
—
Price / book
15.62×
Price / sales
16.13×
EV / sales
15.89×
EV / EBITDA
-61.06×
Profitability
Earnings per share
-$2.06
Return on assets
-20.33%
Return on equity
-30.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
2.67×
Quick ratio
2.38×
Cash ratio
0.98×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$98.12M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TWST, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$118.38M
$110.72M
$103.7M
$99.01M
$96.06M
$92.79M
$88.71M
$84.71M
Cost of revenue
$55.92M
$53.59M
$49.73M
$48.17M
$44.76M
$46.77M
$45.87M
$46.48M
Gross profit
$62.45M
$57.12M
$53.97M
$50.84M
$51.3M
$46.03M
$42.84M
$38.23M
Selling, general and administrative
$80.71M
$76.09M
$69.74M
$63.76M
$63.37M
$63.67M
$56.18M
$53.14M
Research and development
$18.03M
$19.7M
$17.13M
$17.01M
$18.05M
$23.92M
$21.31M
$21.13M
Total operating expenses
$98.73M
$102.99M
$86.87M
$80.77M
$81.42M
$87.59M
$77.48M
$74.28M
Operating income
-$36.28M
-$45.86M
-$32.9M
-$29.93M
-$30.12M
-$41.56M
-$34.64M
-$36.04M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$34.74M
-$43.98M
-$30.25M
-$26.88M
$20.58M
-$39.15M
-$31.5M
-$34.75M
Income taxes
$311K
$43K
$253K
$257K
$191K
$175K
$97K
-$96K
Net income
-$35.05M
-$44.02M
-$30.51M
-$27.14M
$20.39M
-$39.33M
-$31.59M
-$34.66M
Net income attributable to common shareholders
-$35.05M
-$44.02M
-$30.51M
-$27.14M
$20.39M
-$39.33M
-$31.59M
-$34.66M
EBITDA
-$29.5M
-$32.24M
-$26.71M
-$23.93M
-$24.06M
-$35.16M
-$28.26M
-$74.32M
Basic earnings per share
-$0.56
-$0.71
-$0.50
-$0.45
$0.34
-$0.66
-$0.53
-$0.59
Diluted earnings per share
-$0.56
-$0.71
-$0.50
-$0.46
$0.33
-$0.66
-$0.53
-$0.59
Recent news
Company coverage with links to the original publishers.
Twist Bioscience reported Q4 2026 revenue growth of 28% YoY to $126.6M, with AI drug discovery revenue surging 175% to $59.1M. The company achieved positive adjusted EBITDA and plans to expand its DNA synthesis capacity from 10 to 16 writers. Management expects FY2027 revenue of $550-560M (21% growth) and will reinvest profits into capacity and automation rather than seeking external funding.
ADC Therapeutics (ADCT) reported a quarterly loss of $0.16 per share, beating consensus estimates of $0.21 loss, with a 23.81% earnings surprise. Revenue of $21.72 million also exceeded expectations by 5.67%. However, the stock has declined 55.2% year-to-date versus the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
The State Street SPDR S&P Biotech ETF (XBI) is reviewed as a passively managed fund with low costs (0.35% expense ratio) and $10.42 billion in assets. The ETF has delivered strong year-to-date returns of 22.76% and 12-month returns of 39.54%, though it carries high risk with a beta of 0.83 and 27.66% standard deviation. With 167 holdings and a Zacks ETF Rank of 3 (Hold), it offers diversified biotech exposure but faces competition from similar alternatives like IBB and FBT.
The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.
The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.